Phase 1RecruitingPriority 3 · Moderate priorityNCT06420089
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Plain-language summary
This Phase 1 trial is comparing Senza5 CART5 against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 2 US locations.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Senza5 CART5 (DRUG): The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
- Drugs / treatments
- Senza5 CART5
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details